# Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease

J.W. Wieringa [a, *], C.J. van der Woude [b]

[a] Department of Pediatrics, Haaglanden Medical Center and Department of Pediatrics, Subdivision of Infectious Diseases and Immunology, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, Lijnbaan 32, CK The Hague, 2501, the Netherlands
[b] Department of Gastroenterology, Erasmus MC University Medical Center, 's Gravendijkwal 230, 3015, CE, Rotterdam, the Netherlands

## ARTICLE INFO

## ABSTRACT

Current guidelines advise to maintain immunomodulators and biologicals in pregnant patients because relapse of inflammatory bowel is associated with unfavourable pregnancy outcome. With the exception of Methotrexate, IBD therapy seems not to be related to an increase of congenital malformations or infections requiring hospitalisation of the babies, although the effect the on the developing immune system of the exposed infants remains unknown. In this review we will focus on the effect of IBD drugs on health-related outcomes in children taking into account possible long-term effects of biologicals and immunomodulators, which are transferred across the placenta.

© 2019 Elsevier Ltd. All rights reserved.

## Introduction

Pre-conception counselling women with inflammatory bowel disease (IBD) is challenging but extremely important. Many women with IBD are afraid that IBD might lead to complications during pregnancy or immunosuppressive medication might harm the neonate [1]. Voluntary childlessness is increased in women with IBD and is associated with lack of knowledge of how IBD and immunosuppressive medication might influence the outcome of pregnancy and the neonate [2,3]. Women who receive pre-conception counselling are less likely to be voluntarily childless [3]. Relapse of IBD has been associated with unfavourable pregnancy outcomes with an increased risk of spontaneous abortion, prematurity and low birth weight [4,5]. Therefore current guidelines advise to maintain IBD drugs such as immunomodulators and biologicals during pregnancy [6,7]. Most IBD drugs are considered of low risk during pregnancy, since no increase of congenital malformations has been reported so far [8−10]. However the effects on the developing immune system of infants, especially of those drugs transferred across the placenta remain uncertain as published cohorts are mostly small and retrospective.

### Anti-Tumor Necrosis Factor alpha therapy

Anti-Tumor Necrosis Factor alpha (anti TNFα) inhibits the biological function of the pro-inflammatory cytokine TNFα by neutralization of soluble and membrane bound TNFα. Several different TNFα inhibitors have been shown to be effective in IBD and are currently used: Infliximab, Adalimumab and golimumab are all monoclonal (IgG1) immunoglobulins blocking TNFα, whereas certolizumab is a pegylated Fab-fragment binding TNFα [11,12].

Like other maternal immunoglobulins anti TNFα drugs are transferred across the placenta passively in low amounts throughout pregnancy [12]. Nearly all anti -TNFα drugs also have the ability to actively pass the placenta during the second half of

* Corresponding author.
E-mail addresses: j.wieringa@erasmusmc.nl (J.W. Wieringa), c.vanderwoude@erasmusmc.nl (C.J. van der Woude).

pregnancy using the neonatal Fc receptor on the placenta. This results in high concentrations of anti- TNFα in the neonate, sometimes exceeding the maternal concentration by a factor 2 at birth [12–15]. Intrauterine exposure extends beyond the neonatal period because of the long half-life of this biological in infants, which is at least twice as long as in adults [16]. Anti- TNFα can still be detected in the child 12 months after birth [16,17]. Certolizumab pegol does not bind the neonatal Fc receptor and concentrations of certolizumab are very low or undetectable in cord blood [18,19].

Most safety data about the effect of intra uterine exposure are from studies with adalimumab and infliximab. Data on golimumab are scarce [20,21]. A recent case report did however describe maternal-fetal transfer of golimumab resulting in golimumab concentration (with last dose given 4 days before birth) in the neonate of 8 µg/ml (121% of maternal concentration) [20]. Given the mechanism of action the effect of intra uterine exposure to golimumab might be comparable to adalimumab and infliximab. Long-term effects of exposure to certolizumab are probably less likely since certolizumab concentrations are very low or undetectable in cord blood.

### Risk of congenital malformations and unfavourable neonatal pregnancy outcome

Intra uterine exposure of infants to anti TNFα has not been associated with adverse pregnancy outcomes such as spontaneous abortions premature birth, low birth weight or congenital malformations [8–10,22,23].

### Anti TNFα and the developing immune system

Concerns might be raised about the effect of anti TNFα on the developing immune system of the exposed children. Anti TNFα drugs might have a direct effect on the immune system during pregnancy but also on the developing immune system after birth.

TNFα has been shown to be important in the development of the immune system in mice. Mice with a TNFα deficiency show an increased susceptibility to infection, reduced delayed hypersensitivity response and a decreased humoral immune response. Although immunoglobulin class switch does occur in these mice, they have a deregulated humoral response to antigens, exemplified by a lack of splenic primary B cell follicles and follicular dendritic cells [24]. TNFα also regulates growth and functional activities of normal T cells and is able to induce the formation of regulatory T-cells. Hypothetically anti-TNFα could have an effect on the developing immune system in humans as well, although TNFα is not completely absent after intra uterine exposure.

Recently a study of T and B cell subsets in children, in utero exposed to infliximab or adalimumab monotherapy (n = 11), or to a combination of thiopurines with either adalimumab or infliximab (n = 4) was published. Children of mothers with IBD, exposed to certolizumab pegol monotherapy (n = 4) were considered reference population. In children exposed to combination therapy a trend toward reduction in three B cell subsets and lower frequency of certain T cells was seen [25]. It was suggested that the reduction in B cell subsets were an effect of combination therapy rather than purely anti-TNFα since TNF- deficient mice did not exhibit a reduction of plasmablasts or memory B cells. Statistical significance was not reached, but numbers were small.

Extensive immunological tests in another small study have shown a decreased response after mycobacterial challenge, a more immature B and T helper phenotype and a decreased regulatory T cell frequency [26].

Neutropenia has been described in adults using anti-TNFα therapy [27] as well as in infants after intra uterine exposure

[26,28]. In a small case series 4 newborns with in utero exposure to anti-TNFα were reported with severe neutropenia and subsequent development of skin infections (n = 3) and Enterobacter cloacae diarrhea (n = 1). Treatment of the infants consisted of granulocyte-colony stimulating factor (G-CSF) and antibiotics. Neutropenia resolved within the first year of life [28]. In the previously mentioned small study [26] neutrophil counts below the reference range in the cord blood of two out of six neonates exposed to anti-TNFα were found. One of them was also exposed to steroids and the other was exposed to anti-TNFα and azathioprine. A severe neutropenia at 3 months of age in one and moderate neutropenia in two out of six patients was observed. None of them suffered of skin infections [26].

### Vaccination of children after exposure to anti- TNFα therapy

Currently it is advised to avoid live attenuated vaccines (i.e. BCG, measles-mumps, rubella MMR) until the levels of anti-TNFα are undetectable [7,29], as there has been one report of an infant, who died after a Bacillus-Calmette- Guérin (BCG) vaccination associated with exposure to anti-TNFα in utero [30].

Besides safety issues, the effectiveness of vaccination in children exposed to anti-TNFα have has also been questioned. Studies in adults with IBD using immunosuppressive drugs have shown that the response to 23-valent pneumococcal vaccine is decreased [31–33]. The response to conjugated pneumococcal vaccine is better [34,35], but the seroprotective rate 2 months after vaccination is still lower in IBD patients using anti-TNFα (86.6%) than in those patients on non-immunosuppressive drugs (95.5%) [34]. Several studies report insufficient levels of Pertussis antibodies in adults [36–38]. But a more recent study showed that the rate of children and adolescents (11–18 years old) with combined immunosuppression who reached adequate booster response to Pertussis vaccination was 90% and comparable to healthy controls [39].

There have been some studies on vaccination response in infants exposed to anti-TNFα in utero (Table 1), but most studies measured vaccine response cross sectionally at different ages, which makes interpretation of results difficult [14,40–45]. In some of these reported children inadequate response to vaccination was found, but numbers were too small to draw any conclusions. In a retrospective study of 25 children, older than 12 months (14–70 months), who were exposed to infliximab or adalimumab in utero the response on vaccinations for S. Pneumoniae, mumps, measles, rubella and diphtheria were normal in all 15 children measured. Serological response to H Influenzae was detectable in all children, but levels were below protective value in 6 of 17 children. Hypogammaglobulinemia was also found in 7 of 17 children (41%) [46]. In a recent larger study from the same research group, including these previous results, serological response to vaccination to H Influenzae was found to be inadequate in 17 out of 49 (34.7%) exposed children at a mean age of 34 months [44]. Moreover 9 out of 37 children (24.3%) had inadequate response to Mumps measured at age 38.9 months. Interestingly though inadequate responses to H Influenzae and Mumps were also found in the control group. Response to other vaccination including Streptococcus Pneumoniae, tetanus, diphtheria, measles and rubella were considered normal. Interpretation of these data is difficult: measurement of vaccination response should ideally be performed one month after vaccination [47] and in these children, responses were performed almost two years after primary vaccination.

Another study compared vaccination response for H Influenzae and tetanus between 42 children exposed to biologicals and 8 children exposed to either other immunosuppressive drugs or no immunosuppressive drugs. No significant differences were found, but overall response rates were lower than historically reported

**Table 1**
Reported vaccination response after intra uterine exposure to anti-TNFα because of maternal IBD.

| Study | Biological (number of patients) | Age at measurement of response | Outcome vaccination response | Significant other outcomes |
|---|---|---|---|---|
| Bortlik 2014 [46] Retrospective multicentre cohort study | Infliximab (n = 22) Adalimumab (n = 3) | At least one year of age | 6/15 inadequate response to Hib vaccine 15/15 adequate response to *Streptococcus Pneumoniae,* mumps, measles, rubella and diphtheria vaccines | 4/25 serious infections requiring hospitalisation 17/17 T en B cel-subsets normal 7/17 mild hypogamma-globulinemia (IgA and/or IgG) 25/25 normal growth 1/25 mild psychomotor developmental delay |
| Beaulieu 2017 [45] Prospective multicentre cohort study, sub-study of the Pregnancy in IBD and Neonatal Outcomes (PIANO) registry | Infliximab (n = 27) Adalimumab (n = 7) Certolizumab (n = 3) Ustekinumab (n = 2) Natalizumab (n = 2) Vedolizumab (n = 1) | At least 7 months of age | 27/38 adequate response to Hib vaccine 33/41 adequate response to tetanus vaccine Response to Hib and tetanus comparable to 8 controls (maternal IBD not exposed to anti-TNFα; but other immunosuppressive drugs), but lower than historically reported | |
| Duricova 2019 [44] Retrospective multicentre controlled cohort study, including children of the previous published study by Bortlik et al. [46] | Infliximab (n = 54) Adalimumab (n = 18) | Median age 34 months (IQR 16.8—61.0) Median age 38.7 months (IQR 24.9 —67.9) | 17/49 inadequate response to Hib vaccine (also inadequate in 14/16 controls) 9/37 inadequate response to mumps vaccine (also inadequate in 3/13 controls) Adequate response to *Streptococcus Pneumoniae* (45/46), tetanus (47/49), diphtheria (48/49), measles (36/37) and rubella (36/37) vaccines | No increased risk of infections, use of antibiotics or allergies Growth and psychomotor development similar to controls |
| De Lima 2018 [48] Single centre Cross sectional, controlled cohort study | Infliximab (n = 8) Adalimumab (n = 7) | 12 months | 15/15 response to hepatitis B vaccine adequate | Growth, number of infections treated with antibiotics, chronic diseases, allergies, eczema comparable to controls (maternal IBD not exposed to anti-TNFα) |
| Mahadevan 2006 [41] Prospective cohort study, data from the PIANO registry (abstract) | Infliximab (n = 8) | Mean 13 months (6—28 months) | 7/8 adequate response to Hib vaccine 8/8 adequate response to tetanus vaccine | 6/8 normal IgG, IgA; 4/6 low IgM |
| Sheibani 2016 [43] Prospective cohort study, data from the PIANO registry | Infliximab (n = 10) Adalimumab (n = 2) | Median age 10 months (6—28 months | 11/12 adequate response to tetanus vaccine 11/12 adequate response to Hib vaccine | 5/10 low IgM, 10/10 normal IgG and IgA No serious infections |
| Vasiliauskas 2006 [40] casereport | Infliximab (n = 1) | 6 months | adequate response to Hib, *Streptococcus Pneumonia* and tetanus vaccine | Normal T en B cel-subsets, IgG, IgA, IgM and in vitro lymphoproliferative responses to non-specific mitogens Normal growth and development, no infections during first year of life |
| Zelinkova 2011 [14] Prospective case series | Infliximab (n = 4) | 6 months | 2/2 adequate response to Hib and *Streptococcus Pneumonia* vaccines | Normal development and no infections during follow up 4—11 months |

[45]. A study on the effectiveness of hepatitis B vaccination in children born to IBD mothers did not observe a difference between response to hepatitis B vaccination in 15 children exposed to anti TNFα compared to 12 children not exposed to anti TNFα [48].

*Risk of infections after exposure to anti- TNFα therapy*

A higher rate of infections in children exposed to the combination of anti-TNFα and thiopurines in utero was found in a prospective study in 80 children. Children were compared to children exposed to anti TNFα monotherapy, but not to an unexposed group [16]. Larger and more recent studies though seem reassuring on the rate of infections, at least on the rate of infections requiring hospitalisation of children exposed to anti-TNFα.

In a cohort of 53 children, who were exposed to anti TNFα in utero and of whom data were retrospectively collected by using questionnaires, the rate of infections was comparable to non-exposed children during the first year of life. These children, however, were advised not to attend normal day care [9]. A larger European retrospective observational study, also using questionnaires, found an incidence rate of serious infections, requiring

hospitalisation of 2.8% per person in 388 children exposed to anti TNFα with (n = 99) or without (n = 289) thiopurines. This was comparable to children of women with IBD, unexposed to anti TNFα or thiopurines [49]. But the majority of children (62%) were not exposed during the third trimester and data considering anti TNFα concentration in cord blood or children were lacking. None of mentioned studies provide information about the occurrence of mild infections.

A retrospective cohort study using data from the French national health system database identified 799 children born to mothers using anti-TNFα during pregnancy because of IBD [50]. Compared to non-exposed children the anti-TNFα exposed children were more often born prematurely and preterm birth was associated to a higher risk of in-hospital infections. The overall rate of infections (community acquired and in-hospital) was 43.7% and comparable to the non-exposed group. Using a medico-administrative database however cannot exclude some bias: recurrent less severe infections not needing direct medical care will not be reported in these databases but could imply subtle influences on the developing immune system.

Another retrospective cohort study using a medico-

administrative database in Canada identified 100 babies born to 90 mothers using anti-TNFα because of an auto-immune disease [51]. Fifty percent of mothers were diagnosed with IBD. The occurrence of serious infections requiring hospitalisation in these children ranged from 0 to 7% depending on concomitant exposure to other immunosuppressive drugs during pregnancy, but statistical analysis did not show an association between anti-TNFα exposure and serious infections in the first year of life.

Although the rate of infections, requiring hospitalisation are reassuring the fact that these data are generated in a population with high vaccination coverage should be taken into account. In the Netherlands vaccination rates are dropping and this might impose more risk in future.

### Auto immune disease and malignancies

Theoretically transplacental exposure to anti-TNFα might affect anti-tumor surveillance as TNFα amongst others regulates cell proliferation, differentiation, survival and apoptosis [52]. IBD patients treated with anti-TNFα inhibitors in combination with thiopurines seem to have an increased risk of developing lymphoma [53−56].

Currently no increase in neoplasms has been observed in children exposed to anti-TNFα during pregnancy, although the length of follow up is limited [49].

The development of autoimmune diseases such as TNFα agonist-induced lupus-like syndrome (TAILS) might be another concern might be. This has not been reported in children after intra-uterine exposure to our knowledge. The incidence of allergies does not seem to be increased compared to the general population [46,48,49].

### Anti-integrins: vedolizumab

Vedolizumab is an anti-α4β7 integrin IgG1 monoclonal antibody, selectively modulating trafficking of memory B cells to the inflamed gut. Vedolizumab targets the interaction between anti-α4β7 and mucosal vascular adressin cell adhesion molecule 1 (MAdCAM), which is expressed in the gut, but is also expressed by maternal vessels in the placenta [57]. In animal models the importance of integrins during placentation and embryogenesis has been shown [58]. Mutations in the α4 subunit gene in mice cause dysfunctional placentation and consequently to the death of the embryo [59].

Data on vedolizumb during pregnancy are limited. As with other IgG1 antibodies vedolizumab placental transfer is expected, especially during the third trimester. Vedolizumab has a longer half-life than adalimumab or infliximab and would theoretically result in significant concentrations in the neonate, even if vedolizumab would be discontinued in the third trimester [60,61]. But in the Pregnancy in the Inflammatory Bowel Disease and Neonatal Outcome (PIANO) registry the serum level in the exposed child at birth was half of serum level of the mother [62]. Another small report of two pregnant women with IBD also showed lower vedolizumab cord blood levels than maternal levels at birth [63]. Last infusion of vedolizumab in these women had been at 10 and 5 weeks before birth. A low detectable level of vedolizumab was found in one of two children at 6 months of age. In a recent prospective cohort study of 21 pregnant women, spontaneous abortion seemed more frequent in women treated with vedolizumab as compared to anti TNFα or conventional treatment for IBD [64]. The authors suggest that more severe and refractory IBD could be a confounder and explanation for this finding, but larger studies are needed to draw any conclusions.

### Risk of congenital malformations and unfavourable neonatal pregnancy outcome

Theoretically blocking integrin function during pregnancy could impose a higher risk for spontaneous abortion or congenital malformations [58].

A report of the outcome of 24 unplanned pregnancies in women treated with vedolizumab in 6 different clinical trials showed 5 elective abortions, 4 spontaneous abortions and 11 live births. Congenital malformation (corpus callosum agenesis and left frontal polymicrogyria) occurred in one child. Two births were premature. Post marketing safety data of an additional 81 pregnancies in women recorded 4 live births and 11 spontaneous abortions. Data of the other 66 pregnancy outcomes were missing [65].

Recently a Belgian multicentre retrospective cohort study, including 24 pregnancies in 24 women with IBD using vedolizumab, reported 2 spontaneous abortions/still births and 23 life births [66].Two patients continued vedolizumab throughout pregnancy because of persistently active IBD. Four children were born premature and one (part of a twin) was small for gestational age. Congenital malformations occurred in 3 children (hip dysplasia, congenital pulmonary valve stenosis and Hirschsprung disease).

### Vedolizumab and the developing immune system

To date no data are available concerning immunological development in children exposed to vedolizumab during pregnancy. Animal studies in pregnant cynomolgus monkeys receiving 10 mg/kg (expected maximum human dose) or 100 mg/kg (10-fold expected human dose) vedolizumab every 2 weeks, showed no changes in white blood cell counts and differentiation at 28 days, 120 days and 6 months after birth.

### Vaccination of children after exposure to vedolizumab

Data on vaccination response in exposed children is limited. In a study of 54 adults treated with vedolizumab the response to hepatitis B vaccination was comparable to placebo. The response to oral cholera vaccination however was reduced, probably reflecting the gut selective mechanism of action of vedolizumab [67]. In the previous mentioned Belgian study no adverse events after vaccination (including live attenuated rotavirus in 9 children) were observed in 20 exposed children [66]. Beaulieu et al. included one child exposed to vedolizumab in their previous mentioned study on response to vaccination after intra uterine exposure to biologicals [45].

### Risk of infections after exposure to vedolizumab

Data concerning the risk of infection in children who were exposed during pregnancy are scarce. Given the working mechanism of vedolizumab an increased rate of (gastro-intestinal) infections might be expected in exposed children. Safety data in patients with IBD using vedolizumab show no increased risk of infection [68]. In a small prospective study in 21 children treated with vedolizumab respiratory tract infections were the most frequent occurring infections and occurred 5 times during the follow up period of 22 weeks after initiation of vedolizumab [69]. In the Belgian study 1 of 23 children exposed during pregnancy, was admitted to hospital during the first year of life because of fever of unknown origin [66].

### Autoimmune disease and malignancies

During follow up of 23 exposed children no malignancies have

been reported but follow up of infants was short with a median of 23 weeks [66]. The risk of malignancies does not seem to be increased in patients treated with vedolizumab either [68].

## Anti IL12/23: ustekinumab

Ustekinumab is a monoclonal IgG1 antibody that prevents interleukine-12 (IL-12) and interleukine-23 (IL-23) to interact with their receptors on immune cells through binding to the p40 subunit, which is present in both interleukines. IL12 and IL23 play an important role in inflammatory diseases, including psoriasis and IBD [70], but might also play a role in uterine physiology and establishing pregnancy [71]. Ustekinumab is actively transported cross the placenta, especially in the third trimester. Concentrations of ustekinumab in cord blood were higher than maternal serum levels, similar to anti-TNFα [62,72]. In a recent case report of one pregnant women, who continued ustekinumab until 8 weeks before delivery, the cord blood level was almost ten-times higher than the maternal trough level directly after birth [73].

### Risk of congenital malformations and unfavourable neonatal pregnancy outcome

No increased risk of spontaneous abortions or congenital malformations was seen in 65 pregnant women, exposed to at least one dose of ustekinumab (most of them treated for psoriasis, 3 women with IBD) [70,74].

### Ustekinumab and the developing immune system

Immunological studies in infants after intra uterine exposure have not been performed. Animal studies in pregnant macaques, using high doses of ustekinumab showed no adverse effects on their offspring. Immunophenotyping, immunohistopathology of lymphoid tissues and T-dependent antibody responses were normal [75].

### Vaccination of children after exposure to ustekinumab

There are no data on vaccination response in children exposed to ustekinumab during pregnancy, but data in adult patients treated with ustekinumab seem reassuring.

In 60 adults treated because of psoriasis, response to 23-valent pneumococcal vaccine and tetanus toxoid was adequate in 96.6% and 84.7% of respectively [76]. This was comparable to control psoriasis patients not receiving systemic treatment. Recently a another study showed that response rate to hepatitis B vaccination was higher in patients using ustekinumab as compared to patients using infliximab or adalimumab [77].

### Risk of infections after exposure to ustekinumab

Data of patients treated with ustekinumab because of IBD do not show an increased risk for serious infections [70]. To our knowledge there are however no data available about the risk of infection in children exposed in utero.

### Autoimmune disease and malignancies

The risk of autoimmune disease and malignancies after intra uterine exposure is unknown. No increased risk of the occurrence of malignancies has been reported in patients treated with ustekinumab [70].

## JAK inhibitors: tofacitinib

Tofacitinib is an oral inhibitor of the Janus kinase (JAK) family of kinases, including JAK1 and JAK3. Through inhibition of JAK1 and JAK3 tofacitinib inhibits signal transduction of several interleukins and interferon, resulting in immunomodulation [78]. Recently the European Medicines Agency (EMA) has recommended not to prescribe tofacitinib in patients who are at risk of pulmonary thromboembolism as a higher risk of pulmonary thromboembolism has been described in patients with RA using tofacitinib 10 mg twice daily [79].

Studies on transplacental transport are lacking but given the small size of tofacitinib, it is considered reasonable that tofacitinib will be able to cross the placenta [80,81].

### Congenital malformations and unfavourable neonatal pregnancy outcome

Animal studies have shown tofacitinib to be teratogenic in rabbits and in rats using dosages 13 to 146 times the recommended dose of 5 mg twice daily [82]. Amongst others ventricular septal defects, skeletal malformations and reduced foetal weight were described. For this reason the current EMA recommendation is that tofacitinib is contraindicated during pregnancy [79]. Outcomes of tofacitinib safety databases of ulcerative colitis were recently reported and combined with previously reported data from safety databases for rheumatoid arthritis and psoriasis [80,81]. A total of 74 maternal exposed pregnancies were described of which 37 resulted in healthy new-borns. Congenital malformation (pulmonary valve stenosis) was described in 1 neonate. Spontaneous abortion occurred in 12 pregnancies, 13 pregnancies were terminated for medical reasons and in 11 pregnancies outcome was pending or mother was lost to follow up. In addition, amongst 42 maternal exposed pregnancies from non-interventional studies or spontaneous adverse events reporting, 7 healthy new-borns, 1 child with a malformation (ventricular septum defect), 3 spontaneous abortions, 1 medical terminations and 33 cases pending or lost to follow up were described [80]. The risk for malformations or spontaneous abortions seemed consistent with background risk in the general population.

### Tofacitinib and the developing immune system

To our knowledge there are no data on the development of the immune system in children exposed in utero to tofacitinib. Neutropenia has been described in adult patients treated with tofacitinib [83].

### Vaccination after exposure to tofacitinib

There are no reports on vaccination response in children exposed during pregnancy, but concerns might be raised when data on exposed adults are taken into account. In 102 adult patients using tofacitinib for rheumatoid arthritis (RA) vaccination response after polysaccharide pneumococcal vaccine was decreased compared to placebo, whereas response to influenzae vaccine was comparable [84]. Satisfactory response to vaccination, defined as a twofold or more rise against 6 or more of 12 pneumococcal serotypes, was achieved in 45.1% of patients on tofacitinib versus 68.4% of RA patients receiving placebo. In another study amongst 60 adult psoriasis patients using tofacitinib more than 80% of patients had measurable titers to each serotype after 13-valent pneumococcal conjugate vaccination and fourfold rise of tetanus toxoid was seen in 60% of patients [85].

*Risk of infections after exposure to tofacitinib*

In a systematic review and meta-analysis on the efficacy and safety of oral JAK inhibitors in adults with IBD the rate of infections was found to be increased as compared to placebo, particularly for herpes zoster [86]. There no data on the rates of infections after exposure in utero.

*Autoimmune disease and malignancies*

The risk of malignancies or auto immune diseases has not yet been studies in children exposed to oral JAK inhibitors during pregnancy. In adults treated with oral JAK inhibitors the risk for malignancies does not seem to be increased, but most studies are relatively small and follow up was short [86].

## Summarizing data and implications for care of exposed children

Maintaining disease remission during pregnancy in women with IBD is important to secure a healthy outcome of pregnancy for both mother and child. Current guidelines therefore advise to maintain IBD medication, including biologicals during pregnancy. Recent data in children exposed to anti TNFα during pregnancy seem reassuring as far as congenital malformations and serious infections requiring hospital admission are concerned. Effects on the developing immune system however cannot be excluded: one infant died after BCG vaccination and some cases of neutropenia with skin infections needing G-CSF have been reported. Moreover, small studies have shown subtle changes in T and B cell subsets, decreased response after mycobacterial challenge and vaccine response rates lower than historically reported. Furthermore, the reassuring data on infection rates are only in infections requiring hospitalisation and are generated in a population with high vaccination coverage. In the Netherlands vaccination rates are dropping and this might impose more risk in future. Any firm conclusions at this stage are impossible given the small size and retrospective design of most studies.

Parents-to-be should be informed about the limited knowledge on long term effects of exposure to biologicals and JAK inhibitors in utero, the importance of administration of inactivated vaccines and the fact that live-attenuated vaccines should be withheld until biologicals are no longer detectable in their child. Given the limited data on long term effects follow up of children exposed to biologicals seems warranted. We would suggest measuring drug level at birth and to check for neutropenia in cord blood. The functional capacity of the immune system can be evaluated by measuring response to routinely administered inactivated vaccines during the first months of life. If an adequate response is lacking, administrating a booster vaccine might be considered. Follow up in a prospective study design to evaluate the necessity of immunological follow up is suggested.

Practice points

- Relapse of IBD during pregnancy is associated with unfavourable pregnancy outcome. Therefore, current guidelines advise to maintain immunosuppressive drugs during pregnancy.
- The risk of congenital malformation and serious infections requiring hospital admission does not seem to be increased in children exposed to anti TNFα during pregnancy, but the effect on the developing immune system is uncertain. Safety data on children exposed to vedolizumab, ustekinumab and tofacitinib are limited and conclusions on the use of these drugs cannot be drawn.

- Administration of live attenuated vaccines should be withheld as long as the biologicals or JAK inhibitor is still detectable.

Research agenda

- Follow up of children exposed to biologicals during pregnancy in a prospective study design is necessary to evaluate both short term and long-term effects on the developing immune system.
- New biologicals, JAK inhibitors or other first in-class drugs with immune suppressive action require extensive evaluation in pregnancy including placental transfer, drug levels at birth and health-related outcome in new-borns.

## Declaration of competing interest

Jantien Wieringa: None.

## Acknowledgements

## References

[1] Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, Fiorino G, et al. Perception of reproductive health in women with inflammatory bowel disease. J Crohns Colitis 2016;10(8): 886–91.

[2] Selinger CP, Ghorayeb J, Madill A. What factors might drive voluntary childlessness (VC) in women with IBD? Does IBD-specific pregnancy-related knowledge matter? J Crohns Colitis 2016;10(10):1151–8.

[3] Purewal S, Chapman S, Czuber-Dochan W, Selinger C, Steed H, Brookes MJ. Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health. Aliment Pharmacol Ther 2018;48(11–12):1202–12.

[4] Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014;20(6):1091–8.

[5] Gonzalez-Suarez B, Sengupta S, Moss AC. Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: a meta-analysis. World J Gastroenterol 2017;23(45):8082–9.

[6] van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015;9(2):107–24.

[7] Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ. The toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016;150(3):734–57. e731.

[8] Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013;19(17):2591–602.

[9] de Lima A, Zelinkova Z, van der Ent C, Steegers EA, van der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut 2016;65(8):1261–8.

[10] Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology 2017;152(2):451–62. e452.

[11] Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci 2014;1317:32–8.

[12] Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3):286–92. quiz e224.

[13] Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study. Scand J Gastroenterol 2013;48(8):951–8.

[14] Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther

2011;33(9):1053—8.

[15] Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013;11(3):318—21.

[16] Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016;151(1):110—9.

[17] Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med 2018;169(1): 60—1.

[18] Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016;116:7—12.

[19] Mariette X, Forger F, Abraham B, Flynn AD, Molto A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, post-marketing, pharmacokinetic study. Ann Rheum Dis 2018;77(2):228—33.

[20] Benoit L, Mir O, Berveiller P. Treating ulcerative colitis during pregnancy: evidence of materno-fetal transfer of golimumab. J Crohns Colitis 2019;13(5): 669—70.

[21] Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80(4):727—39.

[22] Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20(10):1862—9.

[23] Broms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sorensen HT, Stephansson O, Kieler H. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor Agents during pregnancy. Clin Gastroenterol Hepatol 2016;14(2):234—41. e231-235.

[24] Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;184(4):1397—411.

[25] Kattah MG, Milush JM, Burt T, McCabe Jr RP, Whang MI, Ma A, Mahadevan U. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol 2018;9(4):143.

[26] Esteve-Sole A, Deya-Martinez A, Teixido I, Ricart E, Gompertz M, Torradeflot M, de Moner N, Gonzalez EA, Plaza-Martin AM, Yague J, et al. Immunological changes in blood of newborns exposed to anti-TNF-alpha during pregnancy. Front Immunol 2017;8:1123.

[27] Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012;36(4):312—23.

[28] Guiddir T, Fremond ML, Triki TB, Candon S, Croisille L, Leblanc T, de Pontual L. Anti-TNF-alpha therapy may cause neonatal neutropenia. Pediatrics 2014;134(4):e1189—93.

[29] Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organisation: pregnancy and pediatrics. Am J Gastroenterol 2011;106(2):214—23. quiz 224.

[30] Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4(5):603—5.

[31] Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabo H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012;18(6):1042—7.

[32] Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, et al. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014;8(5):384—91.

[33] Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105(1):148—54.

[34] Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM. High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease. Am J Gastroenterol 2019;114(7):1130—41.

[35] Banaszkiewicz A, Targonska B, Kowalska-Duplaga K, Karolewska-Bochenek K, Sieczkowska A, Gawronska A, Grzybowska-Chlebowczyk U, Krzesiek E, Lazowska-Przeorek I, Kotowska M, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21(7):1607—14.

[36] Caldera F, Saha S, Wald A, Garmoe CA, McCrone S, Megna B, Ley D, Reichelderfer M, Hayney MS. Lower sustained diphtheria and Pertussis

antibody concentrations in inflammatory bowel disease patients. Dig Dis Sci 2018;63(6):1532—40.

[37] Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or Pertussis. Dig Dis Sci 2016;61(10):2972—6.

[38] Dezfoli S, Horton HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, Dubinsky M, Shih DQ, Kaur M, McGovern DP, et al. Combined immunosuppression impairs immunogenicity to tetanus and Pertussis vaccination among patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21(8): 1754—60.

[39] Banaszkiewicz A, Gawronska A, Klincewicz B, Kofla-Dlubacz A, Grzybowska-Chlebowczyk U, Toporowska-Kowalska E, Malecka I, Stryczynska-Kazubska J, Feleszko W, Lazowska-Przeorek I, et al. Immunogenicity of Pertussis booster vaccination in children and adolescents with inflammatory bowel disease: a controlled study. Inflamm Bowel Dis 2017;23(5):847—52.

[40] Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4(10):1255—8.

[41] Mahadevan UKS, Church JA, Vasiliauskas EA, Sandborn WJ, Dubinsky MC. He effect of the effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008;134(Issue 4, Supplement 1). A-69.

[42] Steenholdt C, Al-Khalaf M, Ainsworth MA, Brynskov J. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis 2012;6(3):358—61.

[43] Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The effect of maternal peripartum anti-TNFalpha use on infant immune response. Dig Dis Sci 2016;61(6):1622—7.

[44] Duricova D, Dvorakova E, Hradsky O, Mitrova K, Durilova M, Kozeluhova J, Kohout P, Zarubova K, Bronsky J, Hradska N, et al. Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis 2019;25(4):789—96.

[45] Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol 2018;16(1):99—105.

[46] Bortlik M, Duricova D, Machkova N, Kozeluhova J, Kohout P, Hrdlicka L, Durilova M, Mitrova K, Hradsky O, Bronsky J, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis 2014;20(3):495—501.

[47] Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21(23):3265—72.

[48] de Lima A, Kanis SL, Escher JC, van der Woude CJ. Hepatitis B vaccination effective in children exposed to anti-TNF alpha in utero. J Crohns Colitis 2018;12(8):948—53.

[49] Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, et al. Long-term safety of in utero exposure to anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol 2018;113(3):396—403.

[50] Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, Quantin C, Bardou M. Continuous anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION). Am J Gastroenterol 2018;113(11):1669—77.

[51] Tsao NW, Lynd LD, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study. BMJ Open 2019;9(2): e023714.

[52] Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010;20(2):87—103.

[53] Pereira R, Lago P, Faria R, Torres T. Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy. Drug Dev Res 2015;76(8):419—27.

[54] Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108(1):99—105.

[55] Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011;106(12):2146—53.

[56] Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor Antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. Jama 2017;318(17):1679—86.

[57] Fernekorn U, Butcher EC, Behrends J, Hartz S, Kruse A. Functional involvement of P-selectin and MAdCAM-1 in the recruitment of alpha4beta7-integrin-expressing monocyte-like cells to the pregnant mouse uterus. Eur J Immunol 2004;34(12):3423—13.

[58] Darribere T, Skalski M, Cousin HL, Gaultier A, Montmory C, Alfandari D. Integrins: regulators of embryogenesis. Biol Cell 2000;92(1):5—25.

[59] Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development

1995;121(2):549—60.

[60] Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis 2015;9(4):356—66.

[61] Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet 2017;56(11):1287—301.

[62] Uea Mahadevan. Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry Mahadevan, Uma et al. Gastroenterology 2016;150(4):S91—2.

[63] Julsgaard M, Kjeldsen J, Brock B, Baumgart DC. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Aliment Pharmacol Ther 2018;48(3):386—8.

[64] Bar-Gil Shitrit A, Ben Ya'acov A, Livovsky DM, Cuker T, Farkash R, Hoyda A, Granot T, Avni-Biron I, Lahat A, Goldin E, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol 2019;114(7):1172—5.

[65] Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 2017;45(7): 941—50.

[66] Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis 2019;13(1):12—8.

[67] Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015;64(1):77—83.

[68] Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus Jr EV, Sankoh S, Fox I, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66(5):839—51.

[69] Conrad MA, Stein RE, Maxwell EC, Albenberg L, Baldassano RN, Dawany N, Grossman AB, Mamula P, Piccoli DA, Kelsen JR. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis 2016;22(10): 2425—31.

[70] Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin-23 agents in Crohn's disease. Gastroenterol Clin N Am 2017;46(3):603—26.

[71] van Mourik MS, Macklon NS, Heijnen CJ. Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J Leukoc Biol 2009;85(1):4—19.

[72] Rowan CR, Cullen G, Mulcahy HE, Keegan D, Byrne K, Murphy DJ, Sheridan J, Doherty GA. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn's disease treated until 33 Weeks of gestation. J Crohns Colitis 2018;12(3):376—8.

[73] Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn's disease. J Crohns Colitis 2019;13(2):267—9.

[74] Venturin C, Nancey S, Danion P, Uzzan M, Chauvenet M, Bergoin C, Roblin X, Flourie B, Boschetti G. Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol 2017;17(1):80.

[75] Martin PL, Sachs C, Imai N, Tsusaki H, Oneda S, Jiao Q, Treacy G. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol 2010;89(5):351—63.

[76] Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol JDD 2013;12(10):1122—9.

[77] Haykir Solay A, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccines Immunother 2019;15(5):1177—82.

[78] Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, Doty JL, Elliott EA, Fisher MB, Hines M, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53(24): 8468—84.

[79] Agency EM. Summary of product characteristics Xeljanz (tofacitinib). In, https://wwwemaeuropaeu/en/documents/product-information/xeljanz-epar-product-information_enpdf. 2019.

[80] Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, Zhang H, Graham D, Clowse MEB, Feldman SR, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis 2018;24(12):2494—500.

[81] Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibille D, Chen Y, Frazier D, Geier J, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 2016;39(8): 755—62.

[82] Pfizer: prescribing information july. https://labelingpfizercom/ShowLabelingaspx?id=959#S81; 2019. 2019, accessed 21 august 2019.

[83] Huang F, Luo ZC. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol 2019;38(2):523—34.

[84] Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016;75(4):687—95.

[85] Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol 2018;78(6):1149—55. e1141.

[86] Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50(1):5—23.